⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751918 | 0.84 | LMNA (0.48) | — | |
| SCHEMBL10577675 | 0.83 | NAALAD2 (0.46) | — | |
| SCHEMBL444933 | 0.83 | — | — | |
| SCHEMBL10708151 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL7707644 | 0.81 | NAALAD2 (0.45) | — | |
| SCHEMBL7271346 | 0.79 | NAALAD2 (0.48) | — | |
| SCHEMBL11720895 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL10577709 | 0.77 | HMGCR (0.44) | — | |
| SCHEMBL120318 | 0.77 | — | — | |
| SCHEMBL15100349 | 0.77 | NAALAD2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667054-B2 | chemically linking the taxane to a cell binding agent such as monoclonal antibody for tumor antigen; taxane has extra ether bridge group, and chemical group for conjugation such as mercapto | AVENTIS PHARMA S.A. (FR) | 2010-02-23 | — | — | US | disclosed |
| US-7598290-B2 | Cytotoxic agents comprising new C-2 modified taxanes | IMMUNOGEN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070270482-A1 | Cytotoxic Agents Comprising New C-2 Modified Taxanes | AVENTIS PHARMA S.A. (FR) | 2007-11-22 | — | — | US | disclosed |
| EP-1824858-A2 | CYTOTOXIC AGENTS COMPRISING NEW TAXANES | Aventis Pharma S.A. (FR) | 2007-08-29 | — | — | EP | disclosed |
| EP-1819687-A2 | CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES | Aventis Pharma S.A. (FR) | 2007-08-22 | — | — | EP | disclosed |
| US-20060178427-A1 | Cytotoxic agents comprising new taxanes | AVENTIS PHARMA S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
| EP-1688415-A1 | Cytotoxic agents comprising new C-2 modified taxanes | Aventis Pharma S.A. (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-RE39151-E1 | Process for the preparation and purification of thiol-containing maytansinoids | IMMUNOGEN, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2006061259-A2 | CYTOTOXIC AGENTS COMPRISING NEW C-2 MODIFIED TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061258-A2 | CYTOTOXIC AGENTS COMPRISING NEW TAXANES | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
| EP-1669358-A1 | Cytotoxic agents comprising new taxanes | Aventis Pharma S.A. (FR) | 2006-06-14 | — | — | EP | disclosed |
| EP-1313738-B1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-CONTAINING MAYTANSINOIDS | IMMUNOGEN INC (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1313738-A4 | PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-CONTAINING MAYTANSINOIDS | IMMUNOGEN INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1313738-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-CONTAINING MAYTANSINOIDS | Immunogen, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016368-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-CONTAINING MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| US-6333410-B1 | REDUCTIVE HYDROLYSIS OF C3 ESTER WITH LITHIUM TRIMETHOXYALUMINUM HYDRIDE TO YIELD THE MANTANSINOL; ESTERIFYING THE A DISULFIDE-CONTAINING CARBOXYLIC ACID; REDUCING TO YIELD A THIOL-CONTAINING MAYTANSINOID | IMMUNOGEN, INC. | 2001-12-25 | — | — | US | disclosed |
| EP-0425235-B1 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5416064-A | Antitumor agents | IMMUNOGEN, INC. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5208020-A | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0425235-A2 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1991-05-02 | — | — | EP | disclosed |